Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: AMPYRA

« Back to Dashboard
Ampyra is a drug marketed by Acorda and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in twenty-two countries.

The generic ingredient in AMPYRA is dalfampridine. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dalfampridine profile page.

Summary for Tradename: AMPYRA

Patents:5
Applicants:1
NDAs:1
Suppliers: see list1

Clinical Trials for: AMPYRA

Ampyra for Optic Neuritis in MS
Status: Completed Condition: Multiple Sclerosis; Optic Neuritis

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Active, not recruiting Condition: Non Arteritic Ischemic Optic Neuropathy

A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Status: Completed Condition: Parkinson's Disease; Gait Disorders

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
Status: Completed Condition: Multiple Sclerosis

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
Status: Completed Condition: Healthy

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
Status: Active, not recruiting Condition: Spinal Muscular Atrophy

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury
Status: Recruiting Condition: Spinal Cord Injury

Dalfampridine and Gait in Spinocerebellar Ataxias
Status: Completed Condition: Spinocerebellar Ataxias Type 1; Spinocerebellar Ataxias Type 2; Spinocerebellar Ataxias Type 3; Spinocerebellar Ataxias Type 6

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis
Status: Terminated Condition: Transverse Myelitis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010RXYes5,540,938<disabled><disabled>
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010RXYes<disabled><disabled>
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010RXYes8,440,703<disabled><disabled>
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010RXYes8,007,826<disabled><disabled>
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010RXYes8,354,437<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AMPYRA

Drugname Dosage Strength RLD Submissiondate
dalfampridineExtended-release Tablets10 mgAmpyra1/22/2014

International Patent Family for Tradename: AMPYRA

Country Document Number Publication Date
Spain2367707Nov 07, 2011
Portugal1732548Sep 16, 2011
European Patent Office2377536Mar 06, 2013
Portugal2377536Apr 11, 2013
CroatiaP20110497Aug 31, 2011
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc